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A new technique has successfully established the non-obese diabetic/severely combined immunodeficiency
(NOD/SCID) mouse model of ovarian cancer. Under 4% chloral hydrate (0.1 mL/g dose) anesthesia, female mice
were inoculated with tumor-cell suspension. The expression rate of OVCAR3 to CA125 was assessed using flow
cytometry. The inoculated site was hand palpated and the signs and symptoms related to tumor growth were
observed with the naked eye. The allophycocyanin (APC) indirectly labeled mouse-antihuman CA125 and fluorescein
isothiocyanate (FITC)-labeled anti-mouse MHC Class I molecule (H-2Kd/H-2Dd) were observed using a confocal laser
scanning microscope. The animal model of ovarian cancer constructed using this method can more directly reflect the
characteristics of cancer cells. It provides reliable experimental results and presents a technical platform for the research
of ovarian cancer stem cells.
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There are several methods by which to construct an
animal model of epithelial ovarian cancer: Nude Mice
Model [1] of a subcutaneous transplanted tumor, Model
[2] of an intraperitoneal transplanted tumor, Nude Mice
Model [3] of an omentum transplanted tumor, and
Model [4] of an orthotopic transplanted or metastatic
tumor. Orthotopic transplantation has the potential for
broad application because it provides a microenviron-
ment similar to that of the human body. The present
orthotopic transplantation technique [5-9] is to first
construct a Nude Mice Model of a subcutaneous trans-
planted tumor to supply the organism with cancer-cell
strains, extract a small mass of the tumor tissue, open
the ovarian capsule in the mouse under a dissecting
microscope, and transplant the tissue mass into the
ovarian parenchyma. This technique can only indirectly
reflect the characteristics of ovarian cancer-cell strains.
Moreover, it is a very difficult procedure and requires spe-
cial equipment, such as a dissecting microscope; therefore,
a new technique was used in our experiment: the cell* Correspondence: zhanghui98765@163.com
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chyma of the mouse and successfully established the
NOD/SCID mouse model of ovarian cancer.Materials & methods
Materials
Female mice (non-obese diabetes accompanied by severe
combined immunodeficiency, NOD/SCID), aged 6–8
weeks, and weighing 16–20 g were bred under a specific
pathogen-free (SPF) environment and purchased from the
Experimental Animal Center at Sun Yat-sen University
(YUE DONG Number of Certificate of Conformity:
SCXK2004-0011). The mice were kept in a sterile labo-
ratory at a constant temperature of 25 ± 2°C and at a
constant humidity of 45–50% and were fed inside the
laminar air flow rack. One week later, the mice received
an intraperitoneal injection of etoposide (10 mg/kg,
diluted to 200 mL with Hank’s balanced salt solution
[HBSS]). At the same time, a small piece of an estrogen
sustained-release tablet was inserted using a trocar into
the hypoderm of the neck to lower the immunity of the
mouse and shorten the period of neoplasia. Six days later,
the mice were inoculated with the tumor cell suspension
under 4% chloral hydrate (0.1 mL/g dose) anesthesia.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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was purchased from the Affiliated Cancer Hospital of
Sun Yat-sen University. A 15% fetal calf serum RPMI
1640 culture solution was cultured at 37°C in a 5% CO2
incubator. The RPMI 1640 culture medium, fetal calf
serum, and pancreatic enzyme were purchased from Life
Technologies (USA). Matrigel was purchased from BD
(USA) and the CA125 antigen was purchased from
Abcam (DN: ab1107, Cambridge, UK). Allophycocyanin
(APC)-marked second antibody and fluorescein isothio-
cyanate(FITC)-marked anti-mouse major histocompati-
bility complex (MHC) class I antibody were purchased
from eBioscience, Inc. (San Diego, CA, USA). All the
other reagents were from domestic analytical reagents.
Methods
The expression rate of OVCAR3 to CA125 was mea-
sured using flow cytometry. The OVCAR3 cells in the
exponential phase were collected, 2 μL/106 CA125 cells
were added, and the solution was incubated for 1 hat 4°C.
The cells were then washed 3 times in the serum-free
HBSS, the second antibody was added and incubated at
4°C for 30 min, and the cells were washed again 3 times
in serum-free HBSS and loaded into a flow cytometer.
Routinely digest and collect cells in the exponential
phase, living cells are counted and collected separately
by centrifugation. When the density of the cells reached
5 × 107/mL and 5 × 106/mL, respectively, both of the
solutions were suspended in 50 μL HBSS/Matrigel (1:1).
The suction tube used for drawing up the Matrigel during
the confecting period was precooled for 1 h at 4°C, then
washed twice with 4°C HBSS. While the tube was being
precooled and washed, the Matrigel was laid on the ice.
The mice were randomly divided into groups A and B
with 10 mice in each group. By injecting gentian violet
into 110 mice (220 ovaries) having normal anatomical
structures, it was noted that the maximum amount that
could be injected into the mouse ovary was 20 μL; the
mouse ovary would swell and break when >20 μL were
injected. At 15 μL, the ovarian capsule was still intact;
however, seepage was detected from the gentian violet
injection site. The safe dose was determined to be 10 μL.
At this level, the mouse ovarian capsule was observed after
10 min to be still intact and without any seepage. Each
mouse was given an injection of 10 μL cell suspension in
the right ovary, 1 × 105/10 μL for group A and 2 × 104/
10 μL for group B. Following is a description of the
procedure.
With the mouse under complete anesthesia and in a
prone position, the hair was removed from the area of
the right subcostal and 1 cm from the vertebral column
The area was sterilized with iodine alcohol, and a 1-cm
incision was made parallel to the vertebral column using
ophthalmic scissors The peritoneum was cut open andsuspended with thread, the right ovary was exposed, the
adipose tissue above the ovary was clipped with ophthalmic
blunt-end forceps, and the uterus was clipped using an-
other ophthalmic blunt-end forceps, making sure not to
clip the ovarian capsule. The ovary was removed and, using
the left hand, a 4-grade thread was threaded under the
uterus (1.5 cm from the ovary) to suspend it. The right
hand held the microinjector and used it to withdraw 10 μL
cell suspension, and insert it into the uterine cavity, through
the submucous membrane of the oviduct, and into the
ovarian tissue. When the procedure was finished, the
microinjector was removed (Figure 1) The thread suspend-
ing the uterus and the thread suspending the peritoneum
were then removed, sprayed a few biomedical fibrin glue,
and the uterus and ovary were placed back into the perito-
neal cavity. Last, the peritoneum and the skin were sutured
using a 7-grade absorbable surgical suture. The mice
continued to be fed in an SPF environment after surgery.
Index observation: The inoculation site was palpated
and the signs and symptoms related to tumor growth
were observed, such as reduced subcutaneous fat, palp-
able masses in the abdomen, abdominal distention, a
hump in the abdomen, and reduced activity. Each mouse
was labeled based on the random table and each was
weighed to obtain data to graph any weight changes.
After approximately 50 days, there were signs and symp-
toms of reduced activity. After 3 months, the mice were
anesthetized using the same protocols, both ovaries were
removed, and the abdomen was opened to observe the
status of tumor metastasis.
Pathological examination: Three months after inocula-
tion, the inoculated ovary and the contralateral ovary
were removed, fixed in 4% neutral formalin solution,
embedded in paraffin, assume ordinary section and
stained with hematoxylin and eosin as well as with
immunohistochemical stain to detect the expression of
CA125. The ordinary frozen sections were processed
and labeled with fluorescent antibody. The APC in-
directly labeled mouse-antihuman CA125 and FITC la-
beled anti-mouse MHC Class I molecule (H-2Kd/H-2Dd)
were observed using a confocal laser scanning microscope.
Ethical approval
The ethics committee is “河北大学医学伦理委员会”
(Hebei University Medical Ethics Committee).
Results
Flow cytometer
Flow cytometer testing results showed that >98%
OVCAR3 cells expressed CA125 (Figure 2).
Weight growth graph
A weight growth graph is shown in Figure 3. The line in
the table indicates the growth trend.
Figure 1 Data when mice were injected with cell suspension.
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None of the 20 inoculated mice experienced broken
ovarian capsules or seepage of the cell suspension. Only
1 microscopic neoplasia was observed in group A (1/10).
All of the mice in group B (10/10) were observed as
having ovarian neoplasia (Figure 4-A: before laparotomy,
Figure 4-B: after laparotomy). The Pr values of both
groups were measured using Fisher’s analysis (P < 0.05),
and differences were observed between the 2 groups.
The neoplasia cells in the 10 mice in group B were seen
under the microscope in papillary arrangement. Secre-
tions of papilla branches, glandular lumen in part of the
regions, cubical or short columns of cells with wide
trachychromatic irregular nuclei, and karyokinesis were
observed, corresponding to the basic characteristics of
OVCAR3 cells. In addition, the growth of ovarian cancercould be observed in the ovaries of the aforementioned
10 mice under a confocal laser scanning microscope.
The FITC labeled anti-mouse MHC class I molecules
(H-2Kd/H-2Dd) displayed green light labels in the mice
cells, and the APC indirectly labeled mouse-antihuman
CA125 displayed red light labels in the human epithelial
ovarian cancer cells (Figure 5). In group B, 2 mice were
found with contralateral ovarian metastasis (Figure 6),
1 was also found with 1- to 2-mL ascites and 1 with
hepatic metastasis.
Discussion
The T and B lymphocytes are absent in NOD/SCID mice.
Processing with etoposide and an estrogen sustained-
release tablet 6 days before transplantation decreased the
immunity of the mice, thereby shortening the period of
Figure 2 More than 98% OVCAR3 expressed CA125.
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method in the construction of an animal model of
mammary cancer and identified the markers of mam-
mary cancer stem cells.
The characteristics of our method in constructing the
model of orthotopic transplanted tumor. The animal
model of ovarian cancer is an important method by
which to study the biological behavior of ovarian cancer,
to perform experimental treatments, and to select new
and more effective treatments. 70 years ago, Biskind, G R.
[11] removed the gonad of a mouse and implanted part
or all of the removed ovary into the spleen. Under such
conditions, the ovary remained active, but the gonadal
hormones it generated were inactivated by the liver.Figure 3 Body weight decreased in the two groups of mice in
the beginning as a result of the experimental pretreatment.
Linear A and Linear B group representing growth trend in body weight
of mice in each group. Growth trend in body weight of mice in group
B is less than that in group A.The negative feedback mechanism resulted in an unbal-
anced gonadal hormone level in the mouse; therefore,
neoplasia [11] was formed in the transplanted ovary. At
a later stage19 years ago), Hilfrich [12] found that the
cumulative effect of intravenous injection of dimethyl-
benzanthracene (DMBA) can accelerate neoplasia [12]
of an ovary transplanted into the spleen. Such a method
restricted the model’s broad application because of
redundant experimental procedures and long observa-
tion periods. In recent years, many methods in the
construction of such a model have been reported, such
as subcutaneous, peritoneal, and orthotopic transplant-
ation of tumors. Compared to subcutaneous or peritoneal
transplanted tumor models, the orthotopic transplanted
tumor model can better reflect the biological behavior of
ovarian cancer. Because the ovary of a mouse is small,
(0.5 cm in diameter), there has been no report of directly
inoculating the cell suspension into the ovary. If this
technique can be achieved, the animal model of human
ovarian cancer will better simulate the occurrence and
development of this type of cancer. We will be able to
study not only the cell strain but also the biological
behavior of the primary human ovarian cancer cells.
The present method of constructing the orthotopic
transplanted tumor model can only indirectly reflect the
characteristics of the cell strains, and was restricted to
processing tissue mass but not cell suspension. The dif-
ference between the previous orthotopic transplantation
and our experiment is the direct inoculation of cell sus-
pension into the mouse ovary. This method is the first
of its kind. Because the ovary of the NOD/SCID mouse
is comparatively small, the cancer cells are scattered.
Microinjectors were used to pass through the cornu
uteri and into the ovarian parenchyma to inject the cell
suspension and to avoid the human-made cultivation of
a tumor. In our experiment, 2 cell densities were set up:
1 × 105/10 μL for group A and 2 × 104/10 μL for group
B. The results were that 1/10 in group A and 10/10 in
group B were observed as having ovarian neoplasia.
After analyzing the data, we found that the reason for
such a result was that the ovary of the mouse is small, and
that the high cell concentration might result in insufficient
nutrients to the cells and, ultimately, cell death. Fisher reli-
able inspection results revealed that 2 × 104/10 μL is the
ideal inoculation concentration suitable for the size of the
mouse ovary in this experiment.
Compared to previous methods, this method takes less
time for the neoplasia period, assumes simple operational
techniques, and can be performed under orthophoria
conditions. Using this model, we are able to study not
only the biological characteristics of cell strains, but the
biological characteristics of primary ovarian cancer cells
as well to further lay a foundation for the marker of
ovarian cancer stem cells and provide an important tool
Figure 4 A: Before laparotomy. The injected right bottom side is higher than the surrounding skin. B: After laparotomy. Laparotomy can enable the
observation of the planting of increased ovarian tumors.
Figure 5 Observation of ovary 3 months after inoculated
OVCAR3 cells in group B under × 200 confocal laser scanning
microscope. Green light labels: ovary tissue of mouse. Red light labels:
OVCAR3 transplanted tumor of human epithelial ovarian cancer.
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carrying out experimental treatments, and selecting
more effective treatments.
The Matrigel used in the experiment is a type of protein
extracted from ESH mouse sarcoma, which can produce
basement membranes. It can adjust the biological behavior
of epithelial cells, promote the increment and differenti-
ation, etc. Some experiments [13] have proved that Matrigel
can remarkably promote the formation and incrementFigure 6 Little amount of metastasis of ovarian cancer cells in
contralateral ovary. Immunohistochemical staining test CA125 × 200.
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plasia, and rapid growth, and at the same time, keep
the original differentiation, improve the utilization of
animals, and shorten experimental periods.
The mouse MHC class I molecule (H-2Kd/H-2Dd) is
expressed in nearly all of the mouse tissues, and >99%
OVCAR3 expressed CA125 through flow cytometry.
The results of detecting neoplasia in the ovary of a
NOD/SCID mouse with these 2 markers are objective
and reliable.
Conclusion
The animal model of ovarian cancer constructed under
this method can reflect the characteristics of cancer cells
even more directly than previous models. This model
takes less time for neoplasia, assumes simple techniques,
provides reliable experimental results, and presents a
technical platform for research in ovarian cancer stem
cells. It is worth additional research in the construction
of the orthotopic transplanted tumor model of ovarian
cancer.
Novelty and impact statements
A suspension of ovarian cancer cells were microinjected
directly into a mouse ovary to observe their tumorige-
nicity. This model is a real sense of the orthotopic trans-
plantation tumor model. With this model, we can study
the biological characteristics of ovarian tumor cells, such
as drug resistance and the biological markers for cancer
stem cells.
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